Biocon faces regulatory heat as USFDA flags critical issues at its Bengaluru facility

Pallavi Madhiraju- September 30, 2024 0

In a significant development that has sent shockwaves through the biotechnology industry, Biocon Ltd. has come under fire from the U.S. Food and Drug Administration ... Read More

Biocon and Juno Pharmaceuticals ink game-changing diabetes drug deal

Pallavi Madhiraju- October 7, 2023 0

Biocon Limited, the innovation-driven global biopharmaceutical frontrunner, has made headlines by sealing a significant partnership agreement with Juno Pharmaceuticals, Canada's esteemed specialty pharmaceutical giant. This ... Read More

Biocon Generics acquires US facility for $7.7m, targets two billion tablet capacity

Pallavi Madhiraju- September 2, 2023 0

Biocon Limited, a global leader in the biopharmaceutical industry, has made a landmark announcement: its wholly-owned subsidiary, Biocon Generics Inc., has successfully acquired Eywa Pharma ... Read More

Biocon Biologics wraps up integration of former Viatris biosimilars business

Pallavi Madhiraju- July 5, 2023 0

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful integration of the acquired biosimilars business from Viatris in over 70 countries ... Read More

Biocon Biologics debuts biosimilar HULIO in US market

Pallavi Madhiraju- July 4, 2023 0

In a significant development for healthcare accessibility, Biocon Biologics Ltd (BBL), a subsidiary of Biocon, announced the availability of its biosimilar injection, HULIO (adalimumab-fkjp), in ... Read More

FDA rejects Biocon Biologics BLA for Insulin-R product

Pallavi Madhiraju- January 9, 2023 0

Biocon Limited, an Indian biopharma company, said that its subsidiary Biocon Biologics has been issued a complete response letter (CRL) from the US Food and ... Read More

Biocon Biologics wraps up $3.3bn acquisition of Viatris biosimilars unit

Pallavi Madhiraju- November 30, 2022 0

Biocon said that its subsidiary Biocon Biologics has wrapped up the previously announced $3.3 billion acquisition of the biosimilars business of US-based pharma company Viatris. ... Read More

Biocon partners with Zentiva for European marketing of Liraglutide

Pallavi Madhiraju- November 29, 2022 0

Biocon Limited has entered into a semi-exclusive partnership with Zentiva, a Czech pharma company for marketing its drug-device combination Liraglutide for the treatment and management ... Read More

Biocon Biologics signs licensing deal for two biosimilars with Yoshindo

Pallavi Madhiraju- October 17, 2022 0

Biocon Ltd. said that its subsidiary Biocon Biologics has signed an out-licensing agreement with Japanese pharma company Yoshindo Inc. for commercializing a couple of its ... Read More

Biocon Q4FY22 results : Indian pharma firm net profit down by 6% to Rs 239cr

pallavi123- April 28, 2022 0

Biocon Q4FY22 results : Biocon Ltd has reported a net profit of INR 239 crores for the fourth quarter of the fiscal year 2022 (Q4FY22), ... Read More